U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C18H19NO
Molecular Weight 265.3496
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of DESMETHYLDOXEPIN, (E)-

SMILES

CNCC\C=C1/C2=CC=CC=C2COC3=C1C=CC=C3

InChI

InChIKey=HVKCEFHNSNZIHO-MHWRWJLKSA-N
InChI=1S/C18H19NO/c1-19-12-6-10-16-15-8-3-2-7-14(15)13-20-18-11-5-4-9-17(16)18/h2-5,7-11,19H,6,12-13H2,1H3/b16-10+

HIDE SMILES / InChI

Molecular Formula C18H19NO
Molecular Weight 265.3496
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Z-N-desmethyldoxepin is an active metabolite of doxepin, a tricyclic antidepressant. Z-N-desmethyldoxepin appeared to be a terminal oxidative metabolite, in comparison with isomeric form E-N-desmethyl-doxepin, which is undergone further oxidation under the action of CYP2D6 activity.

Originator

Curator's Comment: College of Pharmacy, University of Saskatchewan

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
Determination of doxepin and desmethyldoxepin in human plasma using liquid chromatography-tandem mass spectrometry.
2000 May 26
Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin.
2000 Oct
Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.
2002 Oct
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].
2006 Jun
Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In 'metabolic consumption' experiments with liver microsomes (having measurable CYP2D6 activity) and initial substrate concentration of 1 microM, the consumption of E-doxepin was greater than that of Z-doxepin. With N-desmethyldoxepin, quinidine inhibited the consumption of E-N-desmethyl-doxepin whereas Z-N-desmethyldoxepin appeared to be a terminal oxidative metabolite. CYP2D6 is a major oxidative enzyme in doxepin metabolism; predominantly catalysing hydroxylation with an exclusive preference for the E-isomers. The relatively more rapid metabolism of E-isomeric forms, and the limited metabolic pathways for the Z-isomers explained the apparent enrichment of Z-N-desmethyldoxepin.
Substance Class Chemical
Created
by admin
on Mon Mar 31 19:09:36 GMT 2025
Edited
by admin
on Mon Mar 31 19:09:36 GMT 2025
Record UNII
J7JTC0A5D6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
(E)-DESMETHYLDOXEPIN
Preferred Name English
DESMETHYLDOXEPIN, (E)-
Common Name English
TRANS-DESMETHYLDOXEPIN
Common Name English
1-PROPANAMINE, 3-DIBENZ(B,E)OXEPIN-11(6H)-YLIDENE-N-METHYL-, (3E)-
Systematic Name English
(E)-3-(DIBENZO(B,E)OXEPIN-11(6H)-YLIDENE)-N-METHYLPROPAN-1-AMINE
Systematic Name English
DOXEPIN HYDROCHLORIDE IMPURITY C [EP IMPURITY]
Common Name English
DOXEPIN IMPURITY C
Common Name English
1-PROPANAMINE, 3-DIBENZ(B,E)OXEPIN-11(6H)-YLIDENE-N-METHYL-, (E)-
Systematic Name English
Code System Code Type Description
PUBCHEM
6433351
Created by admin on Mon Mar 31 19:09:36 GMT 2025 , Edited by admin on Mon Mar 31 19:09:36 GMT 2025
PRIMARY
FDA UNII
J7JTC0A5D6
Created by admin on Mon Mar 31 19:09:36 GMT 2025 , Edited by admin on Mon Mar 31 19:09:36 GMT 2025
PRIMARY
EPA CompTox
DTXSID60217319
Created by admin on Mon Mar 31 19:09:36 GMT 2025 , Edited by admin on Mon Mar 31 19:09:36 GMT 2025
PRIMARY
CAS
67035-76-1
Created by admin on Mon Mar 31 19:09:36 GMT 2025 , Edited by admin on Mon Mar 31 19:09:36 GMT 2025
PRIMARY
CHEBI
142340
Created by admin on Mon Mar 31 19:09:36 GMT 2025 , Edited by admin on Mon Mar 31 19:09:36 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> IMPURITY